JPJacek Pliszczyński

Jacek Pliszczyński

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacek Pliszczyński has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Two Cases of Successful Kidney Transplantation From a 39-Year-Old Male Deceased Donor With Marfan Syndrome: A Case Series

    by Oliwia Wicik, Maksymilian Baryła, Jacek Pliszczyński, Aleksandra Popławska-Ferenc

    BACKGROUND Marfan syndrome is a multisystemic, autosomal dominant connective tissue disorder caused by mutations in the fibrillin-1 gene. It is associated with life-threatening complications, especially aortic aneurysms and dissections, and has a global prevalence of 1 in 3000-5000 individuals. Although kidney transplantation is the standard treatment for end-stage renal disease (ESRD), deceased kidney donors with Marfan syndrome remain uncommon due to concerns about connective tissue fragility. Emerging reports, however, indicate that kidneys from such donors may be safely used. This report describes 2 successful kidney transplantations from a 39-year-old male donor with confirmed Marfan syndrome. CASE REPORT Case 1. The donor died from subarachnoid hemorrhage and had a history of aortic arch replacement for aortic dissection. Both kidneys were retrieved from the retroperitoneal space, prepared according to standard protocols, and stored in University of Wisconsin Store Protect Plus organ preservation solution under static cold storage at 4°C. Case 2. A 59-year-old man with ESRD secondary to diabetic nephropathy underwent his first kidney transplantation. He was hemodialyzed with residual diuresis. The right kidney was transplanted without complications, and the recipient achieved immediate and stable graft function. Case 3. The second recipient was a 34-year-old man with ESRD due to vesicoureteral reflux and obstructive nephropathy, also on hemodialysis with preserved diuresis. Left kidney transplantation proceeded uneventfully. He experienced delayed graft function, which resolved with appropriate management, resulting in satisfactory renal recovery. CONCLUSIONS These cases support the growing evidence that kidneys from donors with Marfan syndrome can function effectively after transplantation. Such donors may represent a valuable and underutilized resource, with the potential to expand the kidney donor pool safely.

  • Open Access

    Vascular Challenges in Horseshoe Kidney Transplantation: A Case Report

    by Maksymilian Baryła, Marcin Dymkowski, Jacek Pliszczynski

    BACKGROUND Horseshoe kidney is a rare congenital anomaly, occurring in approximately 1 in 400 to 1 in 1800 individuals. When considering transplantation, horseshoe kidneys present unique challenges due to vascular and urinary tract anomalies. They can be transplanted either as a whole, en bloc unit or as 2 separate, split fragments. The complexities in vascular and urinary reconstruction require careful consideration to ensure successful transplantation. CASE REPORT We present a case involving the transplantation of a horseshoe kidney from a deceased 36-year-old male donor with confirmed brain death due to intracerebral bleeding. The kidney had a complex vascular arrangement, with 7 arteries, 2 veins, and 2 ureters. A surgical division and vascular reconstruction were performed. The kidney fragments were successfully transplanted into 64- and 65-year-old male recipients. Both grafts exhibited excellent reperfusion, and at 2-month follow-up, both patients demonstrated satisfactory graft function, without dialysis or acute rejection episodes. CONCLUSIONS In light of the ongoing shortage of kidney grafts, horseshoe kidneys represent a valuable yet challenging option for transplantation. While vascular and urinary tract anomalies can complicate their use, this case illustrates that, with meticulous surgical technique, horseshoe kidney transplantation can be both viable and safe. Nevertheless, the absence of standardized guidelines for splitting techniques and pre-procurement anatomical assessment underscores the need for further research and consensus in this area.


  • Open Access

    Surgical Treatment of Wounds Using Stem Cells in Epidermolysis Bullosa (EB)

    by Magdalena Nita, Jacek Pliszczyński, Andrzej Eljaszewicz, Marcin Moniuszko, Tomasz Ołdak, Katarzyna Woźniak, Sławomir Majewski, Cezary Kowalewski, Artur Kamiński, Dariusz Śladowski, et al.

    Epidermolysis bullosa (EB) is a group of hereditary skin diseases, or genodermatoses, characterized by the formation of severe, chronic blisters with painful and life-threatening complications. Despite the previous and ongoing progress in the field, there are still no effective causative treatments for EB. The treatment is limited to relieving symptoms, which—depending on disease severity—may involve skin (blisters, poorly healing wounds caused by the slightest mechanical stimuli, contractures, scarring, pseudosyndactyly) and internal organ abnormalities (esophageal, pyloric, or duodenal atresia; renal failure; and hematopoietic abnormalities). The last decade saw a series of important discoveries that paved the way for new treatment methods, including gene therapy, bone marrow transplantation, cell therapy (allogenic fibroblasts, mesenchymal stem cells [MSCs], and clinical use of induced pluripotent stem cells. Tissue engineering experts are attempting to develop skin-like structures that can facilitate the process of healing to promote skin reconstruction in injuries that are currently incurable. However, this is incredibly challenging, due to the complex structure and the many functions of the skin. Below, we characterize EB and present its potential treatment methods. Despite the cure for EB being still out of reach, recent data from animal models and initial clinical trials in humans have raised patients’, clinicians’, and researchers’ expectations. Consequently, modifying the course of the disease and improving the quality of life have become possible. Moreover, the conclusions drawn based on EB treatment may considerably improve the treatment of other genetic diseases.


  • Results of Renal Transplant From Deceased Anti-hepatitis C Virus Donors, Poland 1998-2012

    by Jacek Pliszczyński, Ksenia Jasztal, Agnieszka Jóźwik, Maciej Kosieradzki, Roman Danielewicz, Piotr Małkowski, Jarosław Czerwiński

  • Open Access

    The epidemiology of hepatocellular cancer in Poland

    by Dariusz Wasiak, Jacek Pliszczyński, Beata Łągiewska, Maurycy Jonas, Mariusz Panczyk, Piotr Małkowski, Wojciech Lisik, Maciej Kosieradzki

    Introduction This article summarize the available data on hepatocellular carcinoma (HCC) epidemiology in Poland. Data regarding the HCC incidence rate are divergent. Statistical data presented by NFZ appear more credible in that matter than data published by the Polish Oncology Center (POC)....


  • Complete Blood Count of Deceased Donors and the Results of Liver Transplantation

    by Patrycja Bartosiewicz, Marek Pacholczyk, Jacek Pliszczyński, Dariusz Wasiak, Maciej Kosieradzki, Piotr Małkowski, Jarosław Czerwiński

    Evaluating donor characteristics is mandatory for the recipients’ safety and aiding predicting outcomes. The aim was to assess whether abnormalities in complete blood count (CBC) of DBD liver donor present risk factors. Early and long-term results [1-year recipient (1RS+/1RS-) and graft (1GS+/1GS-) survival, 5-year recipient (5RS+/5RS-) and graft (5GS+/5GS-) survival rates] of liver transplantation were evaluated in connection with donor CBC [HGB (g/dl), HCT (%), WBC(k/mm3), PLT(k/mm3)] respectively for 2804 transplantations in the years 1998‐2013 and 1724 in the years 1998‐2009. Data originated from Poltransplant’s records. Figure.1 1. Abnormalities in donor CBC do not influence the early and long-term recipient survival. 2.PLT does not affect the early and long-term transplant outcomes. 3.WBC affects early and late graft survival; reaches lower values in donors providing recipients with at least 1 and 5-year graft function, possibly because of the corresponding risk of infection transmission. 4.Significant deviations of HGB and HCT in groups of grafts that survived and not survived five years, do not display clinical justification.

  • Results of Renal Transplant from Deceased Anti-HCV Positive Donors, Poland 1998‐2012

    by Jacek Pliszczynski, Ksenia Jasztal, Agnieszka Jóźwik, Maciej Kosieradzki, Jarosław Czerwiński

    Kidney transplant (kTx) is the best method of renal insufficiency treatment. In dialyzed, mortality rises along the time on dialysis. There is a continuing shortage of organs for transplantation, hence a propensity to expand the donor pool with extended criteria donors, anti-HCV(+) included. In the above case a transmission of HCV genotype to recipient is present. It has been proven that contamination with more than one HCV genotype did not worsen kTx outcomes. There are 2,6% anti-HCV(+) donors in Poland. Utilization is only possible in case of anti-HCV(+) and anti-HCV RNA(+) recipients. Retrospective analysis covered 8675 deceased donors (1998‐2012 Polish data from “Poltransplant”). The early (after 12months) and late (after 60) graft and patient survival was assessed in kTx recipients, with documented (11410/12867) recipient and donor data spanning at least 1 year after kTx. 7016 kTx recipients with known anti-HCV status were included in comprehensive analysis, according to anti-HCV profile of recipient and donor. The results are in absolute and % values, p (<0.05) assessed with chi-square test. 12m survival: (R)recipient (95%), (G)graft (89%), total; R (95% vs 89%, p=0.0004), G (88 vs 79, p=0,0005) in HCV(−) to HCV(+/−) vs HCV(+) to HCV(+); R (95 vs 94, p=0.2), G (88 vs 83, p=0.0003), HCV(−) to HCV(−) vs HCV(−) to HCV(+); R (93 vs 95, p=0.004), G (82 vs 89, p<0.0001) in HCV(+/−) to HCV(+) vs HCV(−) to HCV(−); R (95 vs 89, p<0.0003), G (88 vs 79, p=0.0002) in HCV(−) to HCV(−) vs HCV(+) vs HCV (+)60m survival: R (86%), G (75%), total; R (84 vs 88, p=0.01), G (63 vs 71, p=0.001) in HCV(+/−) to HCV(+) vs HCV(−) to HCV(−); R (88 vs 80, p=0.003) in HCV(−) to HCV(−) vs HCV(+) to HCV(+) bhh. Worst anti-HCV serological profile was HCV(+) to HCV(+), although transplanting HCV(+) to HCV(+) did not worsen outcomes in that group. Worse kTx outcomes of HCV (+) over HCV(−) donors can be attributed to HCV(+) status of the recipient.

  • P037

    by Peter Jindra, Jacek Pliszczynski, Charles Van Buren, Alfred Eaton, Nicholas Woolley, Jerome Saltarrelli, Eva McKissick, Noriel Acorda, Phillip Erice, Angela Hoover, et al.

  • Lack of C1q Reactivity in Post-LVAD Patient Sera.

    by J. Pliszczynski, C. Van Buren, A. Eaton, N. Woolley, J. Saltarrelli, E. McKissick, N. Acorda, P. Erice, A. Hoover, C. Hollingsworth, et al.